Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.19% 52.34 Delayed Quote.-14.75%
ELI LILLY AND COMPANY 0.48% 82.22 Delayed Quote.-3.11%
JOHNSON & JOHNSON -0.65% 122.91 Delayed Quote.-11.45%
MERCK AND COMPANY -0.20% 58.45 Delayed Quote.5.10%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
05/21BRISTOL MYERS SQUIBB : Illumina to Develop Companion Diagnostics for Oncology Im..
AQ
05/21BRISTOL MYERS SQUIBB : to Take Part in UBS 2018 Global Healthcare Conference
AQ
05/21Biohaven pharmaceuticals reports first quarter 2018 financial and recent busi..
AQ
05/21BRISTOL MYERS SQUIBB : Highlights Breadth of Immuno-Oncology-Based Combination R..
AQ
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/17BRISTOL MYERS SQUIBB : Trademark Application for "I CAN WITH RA" Filed by Bristo..
AQ
05/17BRISTOL MYERS SQUIBB : Findings in the Area of Proteins Reported from Bristol-My..
AQ
05/17BRISTOL MYERS SQUIBB : Recent Findings in Laboratory Research Described by Resea..
AQ
05/17BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Co. in the Area of Porp..
AQ
05/17Jounce sags after ICOS mAb readout
AQ
More news
News from SeekingAlpha
05/22Bristol-Myers Squibb (BMY) Presents at UBS Global Healthcare Conference (Tran.. 
05/22CORE BIOTECH BUYS #16 : Taking Advantage Of Weakness To Add To Conviction Ideas 
05/21Premarket analyst action - healthcare 
05/21Jounce Therapeutics Tumbles On ASCO Reveal, Is There Salvageable Data? 
05/21Syndax Falls On ASCO Abstract Results, But Was Its Drop Justified At This Tim.. 
Financials ($)
Sales 2018 21 726 M
EBIT 2018 5 509 M
Net income 2018 4 503 M
Finance 2018 428 M
Yield 2018 3,12%
P/E ratio 2018 18,86
P/E ratio 2019 15,86
EV / Sales 2018 3,95x
EV / Sales 2019 3,64x
Capitalization 86 157 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 58,3 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-14.75%86 157
JOHNSON & JOHNSON-11.45%333 230
PFIZER-1.16%208 479
NOVARTIS-6.55%202 002
ROCHE HOLDING LTD.-8.90%195 055
MERCK AND COMPANY5.10%159 105